A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers
This open-label, multi-center study will assess the efficacy and safety of Zelboraf (vemurafenib) in patients with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom Zelboraf is deemed the best treatment option in the opinion of the investigator. Patients will receive twice daily oral doses of 960 mg Zelboraf until disease progression, unacceptable toxicity, or withdrawal of consent.
The safety and efficacy of Zelboraf in combination with cetuximab in a subset of patients with colorectal cancer will also be assessed.
Study Type: Interventional
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers
Study Start Date: April 2012
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
- Experimental: Colorectal cancer patient subgroup
- Experimental: Solid tumors & Multiple myeloma patients
|Date last updated at source||2017-10-18|
|Study start date||2012-04-01|
|Estimated primary completion date||2016-09-01|